



Press release 2009-03-19

## **C-RAD has signed an agreement with Brigham and Women's Hospital, Boston, USA.**

**C-RAD AB with its three fully owned subsidiaries develops new and innovative solutions for the use in advanced radiation therapy. The subsidiary C-RAD Imaging has signed an agreement for clinical evaluation of its unique GEMini technology with Brigham and Women's Hospital, an affiliate of Harvard Medical School in Boston.**

The GEMini™ family of image detector panels is primarily designed for use in radiation therapy but the panels can also be used in industrial radiography systems. The market potential for C-RAD Imaging's GEM technology is at least 150 MUSD per year. GEMini™ products represent world class performance and comprise state of the art technology including new unique patented inventions. These new inventions enable superior image quality and real time detection combined with lower cost of ownership.

The evaluation of the GEMini detector will be managed by Dr. Piotr Zygmanski, Staff Physicist at Brigham and Women's Hospital (BWH) and Instructor in Radiation Oncology at Harvard Medical School. The detector will initially be evaluated as a so called EPID in radiation therapy followed by a proposal to develop new functionalities to the system. The evaluation process is planned to start at the beginning of the second quarter of 2009.

Erik Hedlund, CEO, C-RAD AB:

"The C-RAD Imaging group is encouraged by the great interest for the GEMini technology and its potential for use in radiation therapy expressed by Dr. Zygmanski at the Department of Radiation Oncology, Brigham and Women's Hospital at Harvard. We are looking forward to a close cooperation with the Department and are excited about the possibilities to add new functionalities to the system."

Piotr Zygmanski, PhD, Staff Physicist at BWH and Instructor in Radiation Oncology, Harvard Medical School confirmed that he is planning to evaluate GEMini for imaging of patient anatomy and verification of deposited dose.

### **For further information:**

Erik Hedlund, CEO C-RAD AB, Telephone 018- 666931, E-mail: erik.hedlund@c-rad.se

### **About C-RAD AB**

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Number of employees are currently 19 people. The activities in C-RAD AB originates in research and development at the Karolinska Institutet in Solna and the The Royal Institute of Technology in Stockholm. Sales of the company's first product, the C-RAD Sentinel™ started during autumn 2006. A co-operation agreement has been signed with the German company LAP. Distribution agreements has also been established for USA, Japan, Korea, China and Italy. C-RAD AB is a listed company on Aktietorget since 23 July 2007.